FLOWMAKER® Achieves Breakthrough in China as it Secures Two Patents

Today, medical device company FineHeart S.A. is thrilled to announce that its revolutionary FLOWMAKER® has been granted two patents in China by the CNIPA – China National Intellectual Property Administration -. This fully implantable cardiac output restoration system (ICOMS) is a groundbreaking solution for patients suffering from severe heart failure, and is sure to make a difference in the lives of many.

With more than 78 patents in 20 families, the French rhythm and electrophysiology cardiologists have designed the world’s first physiological heart assist device, the FLOWMAKER®, for the treatment of severe heart failure.

The latest patents acquired further strengthen the device’s position in the marketplace as the go-to solution for those suffering from this debilitating condition. With its unique concept, design, production, and surgical implantation capabilities, the FLOWMAKER® is revolutionizing the way we treat heart failure.

FineHeart is taking a major step forward in its mission to provide a minimally invasive, highly effective and long-lasting solution to the millions of individuals affected by severe heart failure – with the launch of its first Chinese patents. This move will open up a huge and rapidly growing market, allowing FineHeart to reach more people than ever with its life-saving technology.

The Chinese healthcare market is undergoing a dramatic transformation to meet the needs of its aging population. In the last decade, medical device imports have skyrocketed by 360%, and with more than 200 million people over 65 years old, they are now the largest consumers of healthcare products.

Cardiovascular diseases are the leading cause of death, affecting 300 million Chinese patients, 14 million of whom suffer from severe heart failure. With such a significant demand for healthcare, the Chinese healthcare market stands poised to meet the needs of its aging population.

FineHeart’s FLOWMAKER® is perfectly poised to take advantage of the favorable economic and regulatory environment for medical device innovation in China, providing an attractive solution for the mechanical ventricular assist market with the promise of generous reimbursements. It’s a win-win situation for all involved!

The revolutionary FLOWMAKER® provides a much simpler solution than LVADs, using the natural power of the heart to operate without the need for intraventricular bypass. Weighing in at just 70 g and recharged through the skin, its battery requires minimal energy and eliminates the risk of infection.

With its minimally invasive surgical procedure, the FLOWMAKER® can be implanted with a beating heart, ensuring minimal physiological changes. Adapting to the evolution of the pathology, this miniature heart pump assists the heart and is easily removable, making it a safe and effective option for patients.

Dr. Stéphane Garrigue, cardiologist and co-founder of FineHeart, is proud to introduce the revolutionary FLOWMAKER®. This miniature, mini-invasive, completely implantable left ventricular assistance system is a beacon of hope for thousands of patients suffering from severe heart failure.

With the FLOWMAKER®, these individuals now have the opportunity to regain their vital functions, improve their quality of life, and experience a newfound sense of autonomy, free from the burdens of current devices or those in development.

FineHeart is thrilled to announce that its innovative device has been granted patents in China, where the aging population is facing a resurgence of cardiovascular diseases. This is a major milestone for the company, as it allows them to envision a potential effective treatment for patients with severe heart failure in the country.

Furthermore, FineHeart’s robust intellectual property portfolio serves as a vital asset to protect market share from any competition. The company is determined to continue developing its device and will take the necessary steps to ensure a successful clinical trial.


The revolutionary FLOWMAKER® is the first of its kind – a fully intraventricular, wireless flow accelerator that can be customized to each patient’s needs like a pacemaker. This miniature device, measuring just 10 cm, is implanted using a minimally invasive procedure that typically takes less than 90 minutes.

The FLOWMAKER® does not require aortic bypass surgery, and is powered by a wireless transcutaneous energy transfer system (TET) that eliminates the need for an external driveline. With the FLOWMAKER®, patients can benefit from physiological support synchronized with their heart’s natural contractions while respecting the natural blood flow.

Heart failure is a degenerative disease that progresses to a severe form, second only to cancer as a leading cause of death worldwide. Unfortunately, 200,000 patients annually are not effectively managed due to lack of treatment, resulting in an inability of the heart to contract effectively. With the right care and attention, however, these individuals can be given a new lease on life.

About FineHeart

FineHeart is poised to revolutionize the world of medical devices with its groundbreaking product, FLOWMAKER®. With the potential to treat 200,000 severe heart failure patients a year, FineHeart’s first-in-human trials are expected to launch in 2023.

With an estimated market value of over US$5 billion, FineHeart will start by targeting the 50,000 most severe patients eligible for cardiac assistance. This is a game-changing development with the power to transform the lives of countless people around the world.

FineHeart, founded in 2010 and based in Bordeaux, is a leading innovator in the cardiac health space. Spearheaded by a team of renowned cardiac surgeons and electro-physiologists, the company boasts a portfolio of 78 patents in 20 families.

Led by Dr. Stéphane Garrigue, PhD, CSO and co-inventor of the FLOWMAKER®, Dr. Philippe Ritter, MS, co-inventor of cardiac resynchronization (CRT), and Arnaud Mascarell, FineHeart’s CEO, the company is dedicated to providing the best and most innovative cardiac solutions for its growing list of customers. With close to 50 employees, FineHeart is a leader in the industry, providing life-saving solutions to those in need.

FineHeart is backed by a strong network of public and private investors, including the Lauak Group, Doliam, Med-INNOV, and FineHeart Founders’ Holding. The company also enjoys the support of the European Union, Bpifrance, the New Aquitaine Region, the Centre Region, as well as international private investors, mostly from the cardiology sector. Verve Ventures, Irdi, Aquiti, Galia, Broadview Ventures and M Capital are some of the historical shareholders that have invested in FineHeart.

Leave a Comment